Tempest Therapeutics (NASDAQ:TPST) Stock Price Down 3.9% – Here’s Why

Tempest Therapeutics, Inc. (NASDAQ:TPST) shares fell 3.9% on Wednesday . The company traded as low as $0.9489 and last traded at $0.9511. 83,599 shares were traded during trading, a decline of 51% from the average session volume of 170,982 shares. The stock had previously closed at $0.9902.

Analyst Upgrades and Downgrades

TPST has been the topic of a number of research reports. Zacks Research lowered Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a report on Monday, July 13th. Finally, Wall Street Zen lowered Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Tempest Therapeutics Stock Down 3.9%

The company has a market capitalization of $15.20 million, a PE ratio of -0.16 and a beta of -1.73. The firm has a 50-day moving average of $1.30 and a two-hundred day moving average of $1.91.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). Equities analysts predict that Tempest Therapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Institutional Trading of Tempest Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP acquired a new stake in shares of Tempest Therapeutics during the 4th quarter worth about $33,000. Sabby Management LLC acquired a new position in Tempest Therapeutics in the fourth quarter valued at about $513,000. Finally, Vanguard Group Inc. lifted its position in Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after buying an additional 27,952 shares during the last quarter. 22.52% of the stock is currently owned by hedge funds and other institutional investors.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.